A review of cost‐effectiveness of varenicline and comparison of cost‐effectiveness of treatments for major smoking‐related morbidities (Q33732066)

From Wikidata

Jump to navigation Jump to search

scientific article published on October 4, 2010

Language	Label	Description	Also known as
English	A review of cost‐effectiveness of varenicline and comparison of cost‐effectiveness of treatments for major smoking‐related morbidities	scientific article published on October 4, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

A review of cost‐effectiveness of varenicline and comparison of cost‐effectiveness of treatments for major smoking‐related morbidities (English)

1 reference

10.1111/J.1365-2753.2010.01439.X

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01439.X

16 August 2024

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Koo Wilson

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Miny Samuel

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Evelina A. Zimovetz

1

0000-0002-8939-7838

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21029268

16 August 2024

Stephen M. Beard

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21029268

16 August 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21029268

16 August 2024

publication date

4 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2753.2010.01439.x

1 reference

10.1111/J.1365-2753.2010.01439.X

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01439.X

16 August 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2753.2010.01439.x

1 reference

10.1111/J.1365-2753.2010.01439.X

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01439.X

16 August 2024

Journal of Evaluation in Clinical Practice

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

288-297

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Regional, disease specific patterns of smoking-attributable mortality in 2000.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Economic burden of cardiovascular diseases in the enlarged European Union

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Development of the health and economic consequences of smoking interactive model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Cost-effectiveness of varenicline for smoking cessation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

A systematic review and economic evaluation of statins for the prevention of coronary events.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Tobacco smoking cessation management: integrating varenicline in current practice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Budgetary impact of varenicline in smoking cessation in the United Kingdom

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Healthcare financing systems for increasing the use of tobacco dependence treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2753.2010.01439.X

21 January 2018

Preventing 3 million premature deaths and helping 5 million smokers quit: a national action plan for tobacco cessation

2

1 reference

10.1111/J.1365-2753.2010.01439.X

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01439.X

16 August 2024

The economic impact of smoking in Germany

6

1 reference

10.1111/J.1365-2753.2010.01439.X

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01439.X

16 August 2024

An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation

18

1 reference

10.1111/J.1365-2753.2010.01439.X

https://api.crossref.org/works/10.1111/J.1365-2753.2010.01439.X

16 August 2024

Identifiers

10.1111/J.1365-2753.2010.01439.X

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33732066&oldid=2228476867"